Výsledky vyhledávání - "Busslinger SD"

Akademický článek

Comparison of the tolerability of ¹⁶¹ Tb- and ¹⁷⁷ Lu-labeled somatostatin analogues in the preclinical setting.

Autor: Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland., Mapanao AK; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland., Kegler K; AnaPath Services GmbH, Liestal, 4410, Switzerland., Bernhardt P; Department of Medical Radiation Sciences, Institution of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41345, Sweden.; Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, 41345, Sweden., Flühmann F; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland., Fricke J; Division of Nuclear Medicine, University Hospital Basel, Basel, 4031, Switzerland., Zeevaart JR; Radiochemistry, South African Nuclear Energy Corporation (Necsa), Brits, 0240, South Africa., Köster U; Institut Laue-Langevin, Grenoble, 38042, France., van der Meulen NP; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland.; Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland., Müller C; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland. cristina.mueller@psi.ch.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland. cristina.mueller@psi.ch.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Nov; Vol. 51 (13), pp. 4049-4061. Date of Electronic Publication: 2024 Jul 24.

Zobrazit plný text záznamu

Akademický článek

Terbium-149 production: a focus on yield and quality improvement towards preclinical application.

Autor: Favaretto C; Nuclear Medicine Department, University Hospital Basel, Basel, Switzerland.; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland., Grundler PV; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland., Talip Z; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland., Köster U; Institute Laue-Langevin, Grenoble, France.; Physics Department, ISOLDE/CERN, Geneva, Switzerland., Johnston K; Physics Department, ISOLDE/CERN, Geneva, Switzerland., Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland., Sprung P; Department Hot Laboratory, Paul Scherrer Institute, Villigen-PSI, Switzerland., Hillhouse CC; Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland., Eichler R; Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland.; Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Müller C; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., van der Meulen NP; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland. nick.vandermeulen@psi.ch.; Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland. nick.vandermeulen@psi.ch.

Publikováno v: Scientific reports [Sci Rep] 2024 Feb 08; Vol. 14 (1), pp. 3284. Date of Electronic Publication: 2024 Feb 08.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Albumin-Binding and Conventional PSMA Ligands in Combination with ¹⁶¹ Tb: Biodistribution, Dosimetry, and Preclinical Therapy.

Autor: Tschan VJ; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland., Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland., Bernhardt P; Department of Radiation Physics, Institution of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Grundler PV; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland., Zeevaart JR; Radiochemistry, South African Nuclear Energy Corporation (Necsa), Brits, South Africa., Köster U; Institut Laue-Langevin, Grenoble, France., van der Meulen NP; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland.; Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland; and., Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Müller C; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland; cristina.mueller@psi.ch.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Oct; Vol. 64 (10), pp. 1625-1631. Date of Electronic Publication: 2023 Jul 13.

Zobrazit plný text záznamu

Akademický článek

Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.

Autor: Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland., Becker AE; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland., Vaccarin C; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland., Deberle LM; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland., Renz ML; Merck & Cie KmG, Im Laternenacker 5, 8200 Schaffhausen, Switzerland., Groehn V; Merck & Cie KmG, Im Laternenacker 5, 8200 Schaffhausen, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093 Zurich, Switzerland., Müller C; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093 Zurich, Switzerland.

Publikováno v: Cancers [Cancers (Basel)] 2023 Aug 25; Vol. 15 (17). Date of Electronic Publication: 2023 Aug 25.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Inductively Coupled Plasma Mass Spectrometry─A Valid Method for the Characterization of Metal Conjugates in View of the Development of Radiopharmaceuticals.

Autor: Wallimann RH; Novartis Institutes for Biomedical Research, Novartis, 4056 Basel, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland., Schindler P; Novartis Institutes for Biomedical Research, Novartis, 4056 Basel, Switzerland., Hensinger H; Novartis Institutes for Biomedical Research, Novartis, 4056 Basel, Switzerland., Tschan VJ; Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232 Villigen, Switzerland., Busslinger SD; Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232 Villigen, Switzerland., Kneuer R; Novartis Institutes for Biomedical Research, Novartis, 4056 Basel, Switzerland., Müller C; Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland.; Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232 Villigen, Switzerland., Schibli R; Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland.; Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232 Villigen, Switzerland.

Publikováno v: Molecular pharmaceutics [Mol Pharm] 2023 Apr 03; Vol. 20 (4), pp. 2150-2158. Date of Electronic Publication: 2023 Feb 24.

Zobrazit plný text záznamu

Akademický článek

[ ²²⁵ Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [ ²²⁵ Ac]Ac-PSMA-617.

Autor: Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland., Tschan VJ; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland., Richard OK; AnaPath Services, Hammerstrasse 49, 4410 Liestal, Switzerland., Talip Z; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, Vladimir-Prelog-Weg 1-5/10, ETH Zurich, 8093 Zurich, Switzerland., Müller C; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, Vladimir-Prelog-Weg 1-5/10, ETH Zurich, 8093 Zurich, Switzerland.

Publikováno v: Cancers [Cancers (Basel)] 2022 Nov 17; Vol. 14 (22). Date of Electronic Publication: 2022 Nov 17.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Preclinical investigations using [ ¹⁷⁷ Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer.

Autor: Tschan VJ; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland., Borgna F; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland., Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland., Stirn M; Clinical Laboratory, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, 8057, Zurich, Switzerland., Rodriguez JMM; Laboratory for Animal Model Pathology (LAMP), Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, 8057, Zurich, Switzerland., Bernhardt P; Department of Radiation Physics, Institution of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 41345, Gothenburg, Sweden., Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, 8093, Zurich, Switzerland., Müller C; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland. cristina.mueller@psi.ch.; Department of Chemistry and Applied Biosciences, ETH Zurich, 8093, Zurich, Switzerland. cristina.mueller@psi.ch.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2022 Sep; Vol. 49 (11), pp. 3639-3650. Date of Electronic Publication: 2022 May 30.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Preclinical Investigations to Explore the Difference between the Diastereomers [ ¹⁷⁷ Lu]Lu-SibuDAB and [ ¹⁷⁷ Lu]Lu-RibuDAB toward Prostate Cancer Therapy.

Autor: Borgna F; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI 5232, Switzerland., Deberle LM; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI 5232, Switzerland., Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI 5232, Switzerland., Tschan VJ; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI 5232, Switzerland., Walde LM; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI 5232, Switzerland., Becker AE; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI 5232, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI 5232, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich 8093, Switzerland., Müller C; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI 5232, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich 8093, Switzerland.

Publikováno v: Molecular pharmaceutics [Mol Pharm] 2022 Jul 04; Vol. 19 (7), pp. 2105-2114. Date of Electronic Publication: 2022 May 11.

Zobrazit plný text záznamu

Akademický článek

Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.

Autor: Benešová M; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093 Zurich, Switzerland., Guzik P; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland., Deberle LM; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland., Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland., Landolt T; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093 Zurich, Switzerland., Müller C; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093 Zurich, Switzerland.

Publikováno v: Molecular pharmaceutics [Mol Pharm] 2022 Mar 07; Vol. 19 (3), pp. 963-973. Date of Electronic Publication: 2022 Feb 22.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání